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Published by ElsevierResults. Patients with a GPS of 0 and 1 had a mean
ICU length of stay of 0.8 days, whereas patients with a
GPS of 2 had a mean ICU stay of 5.0 days (p[ 0.004). The
postoperative mortality rate in patients with a GPS of 2
was much higher than in patients with a GPS of 1 and 2,
although it was not statistically significant (p [ 0.083).
Conclusions. A preoperative GPS of 2 effectively pre-
dicts a prolonged ICU stay in patients who undergo
pneumonectomy for cancer. The score may be proposed
as an easy-to-determine, economical, and fast preopera-
tive tool to plan and optimize ICU admissions after
elective pneumonectomy.
(Ann Thorac Surg 2016;102:1898–904)
 2016 by The Society of Thoracic Surgeonslthough it is well known that cancer developmentAhas a genetic basis, there is increasing evidence that
the host systemic inflammatory response, as evidenced
by C-reactive protein, and nutritional status, as evidenced
by serum albumin levels, have an important role in the
progression of a variety of common solid tumors [1].
In 2003, Forrest and colleagues [2] first observed that a
cumulative score based on C-reactive protein and albu-
min may have a prognostic value similar to that of
more conventional measures in patients with inoperable
non-small cell lung cancer (NSCLC) [2]. This score—
subsequently termed the Glasgow prognostic score (GPS)—
also had the advantage of being simple to measure,
routinely available, and well standardized, thus being
easier and faster to use than the conventional combina-
tion of cancer stage and performance status [3]. The
prognostic value of stage and performance status in
oncology patients may be hampered by the fact that theyreflect the patient’s status at a specific point in time,
whereas the GPS reflects current nutritional status and
also predicts continuing nutritional decline [4].
Since then, many studies have reported on the prog-
nostic value of C-reactive protein and other markers of
the systemic inflammatory response in patients with a
wide variety of operable [5] and inoperable cancers [6], as
well as in patients with cancer undergoing chemotherapy
or radiotherapy, or both [7].
To date, however, no study has explored the prognostic
value of the GPS on the acute postoperative course in
patients undergoing major pulmonary resection for lung
cancer.
Considering that the GPS reflects the systemic inflam-
matory state of the patient, as well as the nutritional
status, we suppose that it may have a prognostic value in
inoperable lung cancer but might also be predictive of
acute postoperative outcomes in patients with resectable
disease.
The aim of this study was therefore to examine the
relationship between an inflammation-based prognostic
score (GPS) and the 30-day postoperative course in pa-
tients undergoing pneumonectomy for NSCLC and vali-
date the hypothesis that it may add useful information to
optimize both clinical and management aspects in an
elective setting.0003-4975/$36.00
http://dx.doi.org/10.1016/j.athoracsur.2016.05.111
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Population
This was an observational retrospective study. Data were
collected prospectively and entered into our institutional
general thoracic database at the point of care and
reviewed and double checked retrospectively. Two hun-
dred fifty consecutive standard pneumonectomies per-
formed for NSCLC over a 7-year period were analyzed.
Written informed consent to undergo the procedure
and the use of clinical and imaging data for scientific or
educational purposes, or both, was obtained from all
patients before the operation.
Standard pneumonectomy was defined as the intra-
pericardial or extrapericardial removal of the entire lung
associated with radical mediastinal lymph node dissec-
tion without any resection of mediastinal, chest wall, or
diaphragmatic structures [8]. Patients who underwent
induction chemotherapy were enrolled in the present
study.
Patient Selection and Management
Operability was determined by standard clinical and
radiographic procedures (whole-body computed tomog-
raphy), nuclear imaging (whole-body fluorodeox-
ynucleotide positron emission tomography), and staging
procedures, including endobronchial ultrasonographic
bronchoscopy and transbronchial needle aspiration,
video mediastinoscopy, and mediastinotomy, as
appropriate.
Preoperative respiratory function was assessed
routinely by blood gas analysis, spirometry, and lung
perfusion scanning to identify the functionally prevalent
lung. Patients were always admitted the day before the
surgical procedure unless they required preoperative
management of medical comorbidities, which was
exceedingly uncommon.
Comorbidities were stratified according to an adapted
Charlson comorbidity index [9], with a mean score of 4
(range, 2–6); they included a history of myocardial
infarction, peripheral disease, cerebrovascular disease,
diabetes (without end-organ damage), mild and moderate
liver disease, and moderate kidney disease.
Amoxicillin and clavulanic acid were administered for
the first 5 postoperative days in nonallergic patients, with
the first dose administered before the skin incision [10].
Intraoperative fluid administration was on the order of 5
to 7 mL/kg/h crystalloid infusion, not exceeding a total of
1,500 mL in all cases. Ventilation was managed by a
protective ventilation strategy (tidal volume 6 mL/kg,
driving pressure <20 cm H2O above the positive and
negative expiratory pressure, permissive hypercapnia,
and the preferential use of pressure-limited ventilation
modes) [8].
Thromboprophylaxis was maintained with sequential
compression devices, early ambulation, and low-
molecular-weight heparin delivered subcutaneously
(4,000 IU/d enoxaparin sodium). Postoperative analgesia
was achieved in conjunction with anesthesiologists using
a combination of epidural analgesia (when technicallyfeasible and not contraindicated), patient-controlled
analgesia, and oral and parenteral adjuncts as needed to
improve pulmonary and physical therapy.
Patients were instructed preoperatively regarding
incentive spirometry. Postoperatively they received 2
assisted sessions of chest physiotherapy daily starting on
the first postoperative day and were asked to repeat the
physiotherapy program 6 times during the day until
discharge. Therapeutic bronchoscopy was instituted early
based on clinical findings and correlation with daily chest
films. The thoracostomy tube (a standard 32F thoracic
drainage tube) was usually removed on the third post-
operative day, except in the case of early complications
such as bleeding, chylothorax, or suspected early bron-
chopleural fistula.
Postoperative Complications
Postoperative death was defined as 30-day mortality or
longer if mortality occurred during hospitalization.
Complications were classified according to the Thoracic
Morbidity and Mortality classification system [11] as
minor (grade I and II) and major (grade IIIa, grade IIIb;
grade IVa, grade IVb; grade V).
In-Hospital and ICU Length of Stay
In-hospital length of stay was defined as the time spent in
the hospital from the day of operation (operative day 0) to
discharge. ICU length of stay was defined as the time
spent in the ICU from the day of admission to discharge
to the ward.
Glasgow Prognostic Score
The GPS was constructed as previously described [2]. Pa-
tients with both elevated C-reactive protein (>10 mg/L–1)
and hypoalbuminemia (<35 g/L–1) were allocated to a GPS
of 2; patients in whom only 1 of these biochemical abnor-
malities was present were allocated to a GPS of 1; patients
in whom neither of these abnormalities was present were
allocated to a GPS of 0. Blood samples were collected the
day before the planned operations.
Statistical Methods
Patient characteristics and clinical outcomes or compli-
cations were summarized either by counts and percent or
mean, median, minimum, and maximum for categorical
and continuous variables, respectively. Complications
and 30-day postoperative mortality were cross-tabulated
against the GPS (0, 1, 2) and tested for association
with the Cochran-Armitage test for trend. Counts, mean,
median, minimum, and maximum of ICU stay and in-
hospital stay were also computed and tested for associa-
tion with the GPS using the Kruskal-Wallis test. The risk
of postoperative complications and the risk of an ICU stay
of at least 1 day or longer were estimated by univariate
and multivariable logistic regression models using the
GPS as a predictor and tabulated as odds ratios (ORs)
alongside their 95% confidence intervals (CIs). All tests
were 2-sided and considered significant at the 5% level.
All analyses were conducted using SAS, version 9.3 (SAS
Institute, Cary, NC).
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Population
From January 2004 to December 2011, 250 patients un-
derwent pneumonectomy for NSCLC, 199 (79.6%) of
whom were men. The overall mean age was 63.9 years
(range, 36–85 years; SD, 9.1 years). There were 105 right
pneumonectomies (42%) and 145 left pneumonectomies
(58%). Mean body mass index (BMI) was 25.9 (range,
16.3–44.5; SD, 4.4). Twenty-six patients were never-
smokers (10.4%) and 224 were active or former smokers
(89.6%) at the time of diagnosis. One hundred twenty-
three patients (49.2%) received induction treatment,
whereas 127 patients (51.8%) did not.Table 1. Characteristics of the Study Population
Categorical Variables N (%)
Side
Right 145 (58.0)
Left 105 (42.0)
Sex
Male 199 (79.6)
Female 51 (21.4)
Smoking status
Never 26 (10.4)
Active or former smoker 224 (89.6)
Induction treatments
Yes 123 (49.2)
No 127 (51.8)
GPS
0 137 (54.8)
1 92 (36.8)
2 21 (8.4)
Complications
Cardiac 61 (24.4)
Pulmonary 39 (15.6)
Any 116 (46.4)
30-day mortality 14 (5.6)
Early reoperation 24 (9.6)
Continuous Variables Mean  SD (median)
Age, y 63.9  9.1 (65.3)
Preoperative BMI 26.1  4.4 (25.9)
Preoperative albumin 4.1  0.4 (4.1)
Preoperative PCR 22.5  29.3 (8.0)
Hospital stay, d 7.9  5.2 (7.0)
ICU stay, d 1.2  4.6 (0.0)
FEV1 2.3  0.7 (2.3)
FEV1 (%) 83.4  20.5 (81.7)
DLCO (%) 85.2  25.2 (81.7)
V/Q 37.4  11.5 (39.0)
ppoFEV1 50.8  11.1 (49.1)
ppoDLCO 52.8  19.6 (50.3)
BMI ¼ body mass index; DLCO ¼ diffusing capacity of lung for carbon
monoxide; FEV1 ¼ forced expiratory volume in the first second of
expiration; GPS ¼ Glasgow prognostic score; ICU ¼ intensive
care unit; PCR ¼ polymerase chain reaction; ppo ¼ predicted
post operative; V/Q ¼ ventilation/perfusion.Morbidity, Mortality, Length of Stay, and GPS
The mean preoperative albumin level was 4.1 g/L–1
(range, 2.4–5.2 g/L–1; SD, 4.1 g/L–1), and the mean pre-
operative C-reactive protein level was 8 mg/L–1 (range,
0–138.4 mg/L–1; SD, 29.3 mg/L–1). One hundred thirty-
seven patients were scored as GPS 0; 92 patients were
scored as GPS 1; and 21 patients were scored as GPS 2.
Thirty-day mortality was 5.6% (14 of 250 patients), and the
reoperation rate for early complications was 9.6% (24 of
250 patients). One hundred sixteen patients experienced
any type of complication (overall complication rate,
46.4%), 61 patients had cardiac complications (24.4%),
and 39 patients had pulmonary complications (15.6%)
(Table 1). According to the Thoracic Morbidity and
Mortality classification system, 63 patients (25.2% ) had
minor complications (grade I or grade II), 39 patients
(15.6% ) had major complications (grade III or grade IV),
and 14 patients (5.6) had grade V complications. One
hundred patients were admitted to the ICU (40%), and
among them, 29 were admitted or readmitted urgently
(29%). Nine of 29 patients (31.0%) who ended up urgently
in the ICU died; however, failure to rescue these patients
in the ICU was not associated with GPS (p ¼ 0.736)
(Table 2).
The mean in-hospital stay was 7.9 days (range, 4–48
days; SD, 5.2 days) and the mean ICU stay was 1.2 days
(range, 0–44 days; SD, 4.6 days) (Table 1). Thirty-nine
percent of patients had an ICU stay of 1 to 9 days, and
only 5 (2%) had an ICU stay longer than 19 days (data not
shown). The mean ICU stay for patients with a GPS of 2
was 5.0 days, which was significantly longer than in pa-
tients with GPS of 1 and 0 (p ¼ 0.012) (Table 3). The
postoperative mortality OR for patients with a GPS of 2
was 3.10, which was much higher than in patients with a
GPS of 0 and 1, although it was not statistically significant
(p ¼ 0.083) (Table 4).
All other postoperative variables were not directly
related to the preoperative GPS. Predictors of a signifi-
cantly increased risk of an ICU stay of 1 day or longer in
univariate analysis were age (OR, 1.09; p < 0.001), male
sex (OR, 2.10; p ¼ 0.032), current smoker/ex-smoker statusTable 2. Frequency Distribution of 30-Day Complications and
Side by Glasgow Prognostic Score
Glasgow Prognostic Score
p Value0 1 2
Complications, n (%)a
Lung 18 (13.1) 15 (16.3) 6 (28.6) 0.100
Heart 35 (25.5) 21 (22.8) 6 (28.6) 0.958
Other 47 (34.3) 27 (29.3) 6 (23.8) 0.260
Any complication 73 (53.3) 48 (63.0) 11 (52.4) 0.775
Postoperative mortality 7 (5.1) 4 (4.3) 3 (14.3) 0.288
Side, N (%)
Right 60 (43.7) 36 (39.1) 9 (42.8)
Left 77 (56.2) 56 (60.9) 12 (57.1) 0.651
a Complications are not mutually exclusive categories; thus percentages in
parentheses do not equal 100.
Table 3. Summary Statistics of ICU Length of Stay According
to the Glasgow Prognostic Score
Glasgow
Prognostic
Score N
Mean
(Median)
Minimum/
Maximum
p
Value
ICU stay
(d)
0 137 0.8 (0.0) 0/44
1 92 0.8 (0.0) 0/20 0.012
2 21 5.0 (1.0) 0/38
Hospital
stay (d)
0 131 7.8 (7.0) 4/44
1 90 7.4 (6.0) 4/26 0.275
2 19 11.4 (7.0) 5/48
ICU ¼ intensive care unit.
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p ¼ 0.016) (Table 5). Multivariable analysis (full model)
retained as significant risk factors age (OR, 1.08;
p ¼ 0.004), BMI (OR, 1.10, p ¼ 0.005), and a GPS of 2 (OR,
3.82; p ¼ 0.049). The multivariable analysis (reduced
model) retained as significant risk factors BMI (OR, 1.10;
p ¼ 0.005) and a GPS of 2 (OR, 6.06; p ¼ 0.004) (Table 5,
Fig 1).Comment
Thoracic surgery is 1 of the specialties that uses ICU
resources most often, either electively for monitoringTable 4. Univariate Risk of Postoperative Complications by
Levels of the Glasgow Prognostic Score
Complication
Glasgow
Prognostic
Score OR 95% CI
p
Value
Lung 0 Reference . . .
1 1.29 0.61–2.71 0.552
2 2.64 0.91–7.70 0.103
Heart 0 Reference . . .
1 0.86 0.46–1.60 0.532
2 1.17 0.42–3.24 0.654
Other 0 Reference . . .
1 0.79 0.45–1.41 0.938
2 0.60 0.21–1.73 0.454
Any
complication
0 Reference . . .
1 1.00 0.59–1.70 0.802
2 1.17 0.46–2.95 0.734
Side (left
versus
right)
0 Reference
1 1.21 0.71–2.08 0.483
2 1.04 0.41–2.63 0.936
Postoperative
mortality
0 Reference
1 0.84 0.23–2.97 0.243
2 3.10 0.73–13.1 0.083
CI ¼ confidence interval; OR ¼ odds ratio.high-risk patients in the early postoperative period or in
emergent cases for major cardiorespiratory complications
requiring active life-supporting treatments, accounting
for approximately 10% of all ICU admissions [12, 13].
The increased frequency of surgical procedures for
elderly patients with several underlying comorbidities
has contributed to a growing demand for expensive care;
more specifically, the economic costs of ICU care are also
increasing, amounting to approximately 20% to 30% of
the total in-patient expenditure [14].
Although preoperative evaluation to identify patients at
risk of major complications after pulmonary resection has
been reviewed [15, 16], individual factors predicting the
risk of major complications have been reported by only
1 scoring system designed to predict the risk of ICU
admission [12]. This system was subsequently found to
have only a moderate discriminating ability to predict the
risk of ICU admission when applied to a cohort of pa-
tients in a different institution undergoing lung resection
for NSCLC (area under the receiver operating charac-
teristic curve, 0.66; 95% CI, 0.53–0.79) [17].
In a time of a chronic ICU bed shortages, effective
prediction criteria for postoperative ICU admissions and
length of stay may represent an effective clinical and
management tool. From a clinical standpoint, preventive
measures may be implemented for patients identified to
be at increased risk of a postoperative emergency ICU
admission in an attempt to improve their outcomes.
These patients, for instance, may benefit from direct
admission to the ICU rather than to a step-down unit or
may be kept in the ICU longer if that is where they spend
the first day [9]. In addition, patients can receive more
detailed preoperative counseling about their periopera-
tive risk. From a management point of view, surgical
procedures may be restricted or postponed in patients at
a higher risk of ICU admission to reduce the potential
ICU demand, which is in line with position 9 of The
American Thoracic Society statement on the fair alloca-
tion of ICU resources [18].
Because the increase in major infectious and pulmo-
nary complications after resection can be explained by the
combination of immunodeficiency and weakness of res-
piratory muscles in malnourished patients, the benefit of
intensive nutritional support with branched-chain amino
acids and medication for the improvement of appetite has
been recently suggested for reducing the risks in lung
cancer operations [19].
We have already demonstrated that obese and over-
weight patients undergoing pneumonectomy for lung
cancer have a 5-fold higher pulmonary complication rate
compared with patients with a normal BMI [20]. Although
BMI as a categorical variable did not influence ICU length
of stay in the univariate analysis in the present study, it
was included in the multivariate analysis because of its
borderline value as a continuous variable in the univari-
ate analysis. In other words, the increased risk of
spending 1 or more days in the ICU for patients with a
GPS of 2 (OR, 4.45) is similar to that of patients who were
smokers (current or ex-smokers) (OR, 4.54) (Table 5,
Fig 1). It is well known that the GPS offers interesting
Table 5. Univariate and Multivariate Risk (Odds Ratio)
Estimates of ICU Stay (1 Day vs None)
Univariate Risk Factor
Events/
Patients OR (95% CI) p Value
Age, y 102/250 1.09a (1.05–1.13) <0.001
BMI (continuous) 102/250 1.06a (1.00–1.12) 0.062
FEV1 102/246 0.45
a (0.30–0.69) <0.001
FEV1 % 102/247 0.98
a (0.96–0.99) <0.001
DLCO % 98/241 0.99a (0.98–1.01) 0.321
V/Q 98/234 0.99a (0.96–1.01) 0.200
ppoFEV1 98/232 0.97
a (0.95–1.00) 0.019
ppoDLCO 94/226 1.00a (0.98–1.01) 0.661
Sex
Female 14/51 Reference
Male 88/199 2.10 (1.07–4.12) 0.032
Smoking status
No 4/26 Reference
Yes 76/160 4.98 (1.64–15.1) 0.005
BMI (categorical)
Underweight/normal 35/88 Reference
Overweight 43/116 0.89 (0.51–1.58) 0.169
Obese 24/46 1.65 (0.81–3.39) 0.089
Side
Left 66/145 Reference
Right 36/105 0.63 (0.37–1.05) 0.075
Presurgical treatment
No 51/127 Reference
Yes 51/123 1.06 (0.64–1.75) 0.834
Glasgow prognostic
score
0 51/137 Reference
1 37/92 1.13 (0.66–1.95) 0.140
2 14/21 3.37 (1.28–8.91) 0.017
Glasgow prognostic
score
0-1 88/229 Reference
2 14/21 3.21 (1.25–8.25) 0.016
Multivariate Risk Factors
(Full Model) OR (95% CI) p Value
Age 1.08a (1.03–1.14) 0.004
BMI 1.12a (1.04–1.22) 0.005
FEV1 0.67
a (0.30–1.48) 0.322
ppoFEV1 0.99
a (0.96–1.03) 0.750
Sex
Female Reference
Male 1.70 (0.53–5.42) 0.371
Smoking status
No Reference
Yes 2.71 (0.69–10.7) 0.155
Glasgow prognostic score
0–1 Reference
2 3.82 (1.00–14.5) 0.049
Multivariate Risk Factors
(Reduced Model)b
BMI 1.10a (1.03–1.18) 0.005
(Continued)
Table 5. Continued
Multivariate Risk Factors
(Full Model) OR (95% CI) p Value
Glasgow prognostic score
0–1 Reference
2 6.06 (1.81–20.4) 0.004
a For each unit increase. b stratified by age.
Italics represent only statistically significant values.
Between-model c2 comparison, p ¼ 0.435.
BMI ¼ body mass index; CI ¼ confidence interval; DLCO ¼
diffusing capacity of lung for carbon monoxide; FEV1 ¼ forced expi-
ratory volume in the first second of expiration; ICU ¼ intensive care
unit; OR ¼ odds ratio; ppo ¼ predicted post operative; V/Q ¼
ventilation/perfusion.
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different types of solid tumors, both in resectable stages
and in advanced (metastatic) stages, who are receiving
chemotherapy [21–24]; moreover, it has been demon-
strated that the GPS is a useful prognostic indicator of the
overall survival in patients undergoing lung cancer op-
erations, mainly elderly patients with clinical stage I
NSCLC. In addition, it predicts worse overall survival for
patients with small-cell lung cancer [25–28]. Conversely,
the GPS has never been used as an immediate short-term
prognostic factor, and hence no data are available on its
efficacy in predicting the postoperative course in patients
undergoing major pulmonary resection for lung cancer.
The GPS predictive value for postresectional admission
and ICU length of stay after pneumonectomy may result
from the fact that both nutritional status and systemic
inflammation are severely impaired in these very fragile
patients, who benefit maximally from ICU care and thus
spend more days in the ICU after surgical procedures.
We have previously demonstrated that standard
pneumonectomy is a safe procedure even after induction
chemotherapy, with a mortality rate on the order of 5%,
although it increases in patients older than 70 years [8]. In
the present study, the univariate analysis did not show
any significant correlation with presurgical treatments.
Limitations of the Study
Although data were collected prospectively and entered
into our institutional general thoracic database at the
point of care, this is an observational retrospective study
and thus suffers from the common bias of a non-
randomized retrospective study. Moreover, although the
reported series represents 1 of the largest in the modern
literature, it comes from a single-institution experience,
and thus the criteria of ICU admissions and discharge
may be influenced not only by clinical factors but also by
structural conditions and triage pressure.
Conclusions
AGPSof 2 effectivelypredicts prolonged ICU lengthof stay
in patients undergoing pneumonectomy for lung cancer.
TheGPSmay be used as an economical easy-to-determine
tool to select patients needing postoperative ICU
Fig 1. Multivariate risk estimates for intensive care unit (ICU) stay. (BMI ¼ body mass index; DLCO ¼ diffusing capacity of lung for carbon
monoxide; FEV1 ¼ forced expiratory volume in the first second of expiration; ppo ¼ predicted post operative; V/Q ¼ ventilation/perfusion.)
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tion of ICU resources in high-volume thoracic surgical
centers. Further studies are required to extend the use of
the GPS as a prognostic tool for all major lung resections.References
1. Proctor MJ, Morrison DS, Talwar D, et al. An inflammation-
based prognostic score (mGPS) predicts cancer survival in-
dependent of tumour site: a Glasgow inflammation Outcome
Study. Br J Cancer 2011;104:726–34.
2. Forrest LM, McMillan DC, McArdle CS, Angerson WJ,
Dunlop DJ. Evaluation of cumulative prognostic scores based
on the systemic inflammatory response in patients with
inoperable non-small cell lung cancer. Br J Cancer 2003;89:
1028–30.
3. Forrest LM, McMillan DC, McArdle CS, Angerson WJ,
DunlopDJ. Comparison of an inflammation-based prognostic
score (GPS) with performance status (ECOG) in patients
receiving platinum-based chemotherapy for inoperable non-
small cell lung cancer. Br J Cancer 2004;90:1704–6.
4. Brown DJF, Milroy R, Preston T, McMillan DC. The rela-
tionship between an inflammation-base prognostic score
(Glasgow Prognostic Score) and changes in serum
biochemical variables in patients with advanced lung and
gastrointestinal cancer. J Clin Pathol 2007;60:705–8.
5. Roxburgh CS, McMillan DC. Role of systemic inflammatory
response in predicting survival in patients with primary
operable cancer. Future Oncol 2010;6:149–63.6. Clarke SJ, Chua W, Moore M, et al. Use of inflammatory
markers to guide cancer treatment. Clin Pharmacol Ther
2011;90:475–8.
7. McMillan DC. The systemic inflammation-based Glasgow
Prognostic Score: a decade of experience in patients with
cancer. Cancer Treat Rev 2013;39:534–40.
8. Leo F, Solli P, Veronesi G, et al. Does chemotherapy increase
the risk of respiratory complications after pneumonectomy?
J Thorac Cardiovasc Surg 2006;132:519–23.
9. Charlson ME, Pompei P, Ales KL, Mackenzie CR. A new
method of classifying prognostic comorbidity in longitudinal
studies: development and validation. J Chronic Dis 1987;40:
373–83.
10. Chang SH, Krupnick AS. Perioperative antibiotics in thoracic
surgery. Thorac Surg Clin 2012;22:35–45.
11. Ivanovic J, Al-Hussaini A, Al-Shehab D, et al. Evaluating the
reliability and reproducibility of the Ottawa Thoracic
Morbidity and Mortality classification system. Ann Thorac
Surg 2011;91:387–93.
12. Brunelli A, Ferguson MK, Rocco G, et al. A scoring system
predicting the risk for intensive care unit admission for
complications after major lung resection: a multicenter
analysis. Ann Thorac Surg 2008;86:213–8.
13. Parker A, Wyatt R, Ridley S. Intensive care services; a crisis of
increasing expressed demand. Anaesthesia 1998;53:113–20.
14. Halpern NA, Bettes L, Greenstein R. Federal and nationwide
intensive care units and healthcare costs: 1986-1992. Crit
Care Med 1994;22:2001–7.
15. Deslauriers J, Ginsberg RJ, Piantadosi S, Fournier B. Pro-
spective assessment of 30-day operativemorbidity for surgical
resections in lung cancer. Chest 1994;106(6 Suppl):329S–30S.
1904 PETRELLA ET AL Ann Thorac Surg
GLASGOW PROGNOSTIC SCORE AND PNEUMONECTOMY 2016;102:1898–904
G
E
N
E
R
A
L
T
H
O
R
A
C
IC16. Stephan F, Boucheseiche S, Hollande J, et al. Pulmonary
complications following lung resection: a comprehensive
analysis of incidence and possible risk factors. Chest
2000;118:1263–70.
17. Okiror L, Patel N, Kho P, et al. Predicting risk of intensive
care unit admission after resection for non-small cell lung
cancer: a validation study. Interact Cardiovasc Thorac Surg
2012;14:31–3.
18. Fair allocation of intensive care unit resources. American
Thoracic Society. Am J Respir Crit Care Med 1997;156(4 Pt 1):
1282–301.
19. Thomas PA, Berbis J, Falcoz PE, EPITHOR Group. National
perioperative outcomes of pulmonary lobectomy for cancer:
the influence of nutritional status. Eur J Cardiothorac Surg
2014;45:652–9.
20. Petrella F, Radice D, Borri A, et al. The impact of preoperative
body mass index on respiratory complications after pneu-
monectomy for non-small-cell lung cancer. Results from a
series of 154 consecutive standard pneumonectomies. Eur J
Cardiothorac Surg 2011;39:738–44.
21. Alifano M, Mansuet-Lupo A, Lococo F, et al. Systemic
inflammation, nutritional status and tumor immune micro-
environment determine outcome of resected non-small cell
lung cancer. PLoS One 2014;9:e106914.
22. Pinato DJ, Shiner RJ, Seckl MJ, Stebbing J, Sharma R,
Mauri FA. Prognostic performance of inflammation-basedprognostic indices in primary operable non-small cell lung
cancer. Br J Cancer 2014;110:1930–5.
23. Alifano M, Falcoz PE, Seegers V, et al. Preresection serum C-
reactive protein measurement and survival among patients
with resectable non-small cell lung cancer. J Thorac Car-
diovasc Surg 2011;142:1161–7.
24. Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive
protein is associated with incident cancer and survival in
patients with cancer. J Clin Oncol 2009;27:2217–24.
25. Kawashima M, Murakawa T, Shinozaki T, et al. Significance
of the Glasgow Prognostic Score as a prognostic indicator for
lung cancer surgery. Interact Cardiovasc Thorac Surg
2015;21:637–43.
26. Miyazaki T, Yamasaki N, Tsuchiya T, et al. Inflammation-
based scoring is a useful prognostic predictor of pulmo-
nary resection for elderly patients with clinical stage I
non-small cell lung cancer. Eur J Cardiothorac Surg
2015;47:e140–5.
27. Tomita M, Ayabe T, Chosa E, Nakamura K. Prognostic sig-
nificance of pre- and postoperative Glasgow prognostic score
for patients with non-small cell lung cancer. Anticancer Res
2014;34:3137–40.
28. Zhou T, Hong S, Hu Z, Hou X, et al. A systemic
inflammation-based prognostic scores (mGPS) predicts
overall survival of patients with small-cell lung cancer.
Tumour Biol 2015;36:337–43.
